e-learning
resources
Munich 2006
Tuesday 05.09.2006
Pathophysiology and other related issues of interstitial lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Expression and clinical importance of Fas/Fas ligand system in interstitial lung diseases (ILD)
G. Pinis, J. Szczeklik, K. Sladek, B. Balicka, J. Soja, P. Kopinski, J. Golinska, T. Iwaniec (Krakow, Poland)
Source:
Annual Congress 2006 - Pathophysiology and other related issues of interstitial lung disease
Session:
Pathophysiology and other related issues of interstitial lung disease
Session type:
Electronic Poster Session
Number:
4272
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Pinis, J. Szczeklik, K. Sladek, B. Balicka, J. Soja, P. Kopinski, J. Golinska, T. Iwaniec (Krakow, Poland). Expression and clinical importance of Fas/Fas ligand system in interstitial lung diseases (ILD). Eur Respir J 2006; 28: Suppl. 50, 4272
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
Pulmonary sarcoidosis
Related content which might interest you:
Enhanced expression of Fas ligand (FasL) in fibrotic interstitial lung diseases (ILDs). The possible role of membrane-bound FasL form
Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis
Year: 2011
Fas Ligand (FasL) expressed on alveolar lymphocytes (AL) plays role in progression of interstitial lung diseases (ILD) but not in local induction of immune cells apoptosis
Source: Eur Respir J 2005; 26: Suppl. 49, 542s
Year: 2005
Cykine/receptor inflammatory profile in different types of idiopathic intestitial pneumonias (IIPs). Key role of Fas Ligand recruvation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
The death receptors (DRs) expressed on alveolar lymphocytes (AL) in interstitial lung diseases (ILD) participate in apoptosis regulation
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012
Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Low apoptosis rate as a reason of local immune cell accumulation in interstitial lung diseases (ILD). The role of cytokine network
Source: Eur Respir J 2006; 28: Suppl. 50, 826s
Year: 2006
Differential expression of stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis between idiopathic pulmonary fibrosis and interstitial pneumonia associated with collagen vascular disease: a bronchoalveolar la
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Increased expression of a proliferation-inducing ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: A possible link between COPD and lung cancer?
Source: International Congress 2016 – Mechanisms of disease
Year: 2016
αVβ6 integrin expression in interstitial lung diseases
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009
TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
Expression of interleukin-27 (IL27) in human lower airways. Pathophysiological implications in pulmonary sarcoidosis (PS)
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Toll like receptor 4 activation upregulates miR-181b attenuating pulmonary fibrosis via targeting TGFBR1
Source: International Congress 2015 – Latest news on miRNAs in pulmonary research
Year: 2015
Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD)
Source: Eur Respir J 2007; 30: Suppl. 51, 110s
Year: 2007
Expression of TGF-β1 and TGFβ receptors in lung tissue of patients with idiopathic interstitial pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 312s
Year: 2002
Chemokine receptor expression and function of infiltrated neutrophils in inflammatory lung diseases
Source: Eur Respir J 2006; 28: Suppl. 50, 856s
Year: 2006
Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept